Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 4/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | ATM | Q13315 | 3/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | HTT | P42858 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13636390 | 1.00 | GAA (0.52) | GAAKMT2AMEN1ATMNPSR1 | |
| SCHEMBL6562182 | 0.83 | GAA (0.46) | GAAKMT2AMEN1MAPTTHRB | |
| SCHEMBL6562185 | 0.83 | GAA (0.46) | GAAKMT2AMEN1MAPTTHRB | |
| SCHEMBL10947371 | 0.82 | GAA (0.49) | GAAKMT2AMEN1ATMNPSR1 | |
| SCHEMBL16563870 | 0.82 | ESR1 (0.54) | GAAKMT2AMEN1ATMNPSR1 | |
| SCHEMBL12741450 | 0.82 | ESR1 (0.54) | GAAKMT2AMEN1ATMNPSR1 | |
| SCHEMBL10874676 | 0.82 | ESR1 (0.54) | GAAKMT2AMEN1ATMNPSR1 | |
| SCHEMBL13035863 | 0.81 | GAA (0.56) | GAAKMT2AMEN1ATMMAPT | |
| SCHEMBL2777133 | 0.80 | GAA (0.50) | GAAKMT2AMEN1ATMLMNA | |
| SCHEMBL1546560 | 0.80 | GAA (0.50) | GAAKMT2AMEN1ATMMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108822135-A | A kind of synthetic method of the cyclosubstituted thieno of azepine [3,2-d] thiazole and its derivative | 湘潭大学 | 2018-11-16 | — | — | CN | claimed |
| EP-0557274-B1 | RECOVERY OF PALLADIUM | HENKEL CORP (US) | 1994-09-14 | — | — | EP | claimed |
| EP-0557274-A1 | RECOVERY OF PALLADIUM. | HENKEL CORP (US) | 1993-09-01 | — | — | EP | claimed |
| WO-1992008813-A1 | RECOVERY OF PALLADIUM | HENKEL CORPORATION (US) | 1992-05-29 | — | — | WO | claimed |
| CN-108822135-A | A kind of synthetic method of the cyclosubstituted thieno of azepine [3,2-d] thiazole and its derivative | 湘潭大学 | 2018-11-16 | — | — | CN | disclosed |
| US-9725423-B2 | Tetrazolinone compound and applications thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-08-08 | — | — | US | disclosed |
| US-9725423-B2 | Tetrazolinone compound and applications thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-08-08 | — | — | US | disclosed |
| US-20150299146-A1 | TETRAZOLINONE COMPOUND AND APPLICATIONS THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-10-22 | — | — | US | disclosed |
| US-5654458-A | PALLADIUM CHLORIDE COMPLEX WITH ETHER OXIME | HENKEL CORPORATION (US) | 1997-08-05 | — | — | US | disclosed |
| EP-0557274-B1 | RECOVERY OF PALLADIUM | HENKEL CORP (US) | 1994-09-14 | — | — | EP | disclosed |
| EP-0557274-A1 | RECOVERY OF PALLADIUM. | HENKEL CORP (US) | 1993-09-01 | — | — | EP | disclosed |
| WO-1992008813-A1 | RECOVERY OF PALLADIUM | HENKEL CORPORATION (US) | 1992-05-29 | — | — | WO | disclosed |
| US-4032644-A | HYPOLIPIDEMIC AGENTS | SANDOZ, INC. (US) | 1977-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150299146-A1 | TETRAZOLINONE COMPOUND AND APPLICATIONS THEREOF | RTN3, CYCS, ATL3 | GAA 4133/4885KMT2A 3298/4885MEN1 2138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.